Related Experiment Video

Updated: May 27, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN

Tomas Kovarnik1, Gary S Mintz, Hana Skalicka

  • 12nd Department of Medicine, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. tomas.kovarnik@vfn.cz

Circulation Journal : Official Journal of the Japanese Circulation Society
|November 15, 2011
PubMed

Insights

Aggressive dual lipid-lowering therapy with statin and ezetimibe promotes atherosclerosis regression in patients with stable angina. This approach reduces atheroma volume, unlike standard therapy, but doesn't significantly alter plaque composition.

Area of Science:

  • Cardiology
  • Atherosclerosis Research
  • Lipid Metabolism

Background:

  • Limited research exists on coronary atherosclerosis changes during dual lipid-lowering therapy.
  • Statin and ezetimibe combination therapy is increasingly used for lipid management.

Purpose of the Study:

  • To investigate the effects of aggressive dual lipid-lowering therapy (statin + ezetimibe) on coronary atherosclerosis progression.
  • To compare aggressive therapy with standard therapy in patients with stable angina.

Main Methods:

  • Eighty-nine patients with stable angina were randomized to aggressive (atorvastatin 80mg + ezetimibe 10mg) or standard therapy.
  • Coronary arteries were assessed using intravascular ultrasound and virtual histology over 12 months.

Main Results:

  • Aggressive therapy significantly decreased percent atheroma volume (PAV) (-0.4%) compared to standard therapy (+1.4%).
  • Atherosclerosis regression (increased lumen volume + decreased PAV) was more frequent in the aggressive group (40.5% vs. 14.9%).
  • Target LDL cholesterol <2mmol/L, multiple risk factors, and reduced VCAM-1 predicted regression.

Conclusions:

  • Dual lipid-lowering therapy initiates atherosclerosis regression.
  • While effective in reducing atheroma volume, it does not significantly alter plaque composition.
  • A shift towards more calcified and necrotic plaque components occurred in both groups over time.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...